Palo Santo

Data updated July 3, 2026

U.S.-based; public materials do not list a full street address, United States

Palo Santo is a venture capital fund focused on neuroscience and mental health innovation, with an explicit emphasis on next-generation psychedelic therapeutics and enabling technologies. Its public materials describe the firm as investing across novel CNS therapeutics, digital and clinical technologies, and related brain-health infrastructure.

The firm is notable in the psychedelic ecosystem because its portfolio includes multiple companies working on psychedelic medicines, serotonergic agonists, ketamine-assisted care, and related CNS drug discovery. Palo Santo also highlights portfolio outcomes such as pharma acquisitions and FDA breakthrough designations across its neuroscience and psychedelic focus areas.

Investor Context

Venture Capital

Investment Context

This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage signals include Seed, Series A/B, and Growth / Late Stage. Public focus areas include Drug Development, Digital Therapeutics & Platforms, and Clinical Infrastructure.

Public Portfolio Examples

Gilgamesh Pharmaundisclosed
Transcend Therapeuticsundisclosed

Palo Santo presents itself as a U.S.-based venture firm investing in the intersection of neuroscience, mental health, and psychedelic therapeutics. Its portfolio orientation spans drug development and supporting platforms, with public examples including clinical-stage psychedelic and neuroplasticity-focused companies, ketamine-assisted therapy services, and other brain-health technologies. The firm’s public positioning suggests an investment strategy centered on breakthrough clinical progress in mental health rather than a single modality, while still maintaining a clear psychedelic thesis.

Investor Type

Venture Capital Fund

Geographic Scope

Global

Psychedelic Focus

Explicit Psychedelic Focus

Engagement

Active

Investment Stage Focus

SeedSeries A/BGrowth / Late Stage

Investment Focus Areas

Drug DevelopmentDigital Therapeutics & PlatformsClinical Infrastructure